Professional Overview

Ines Palomares Sancho is a seasoned professional currently serving as the Director, Global RWE & Health Outcomes Research Lead (GenMed) at GSK, based in Madrid, Spain. Her key expertise areas include health outcomes research and real-world evidence, with a focus on the pharmaceutical industry.

Experience Summary

Current Role

Ines Palomares Sancho is currently the Director, Global RWE & Health Outcomes Research Lead (GenMed) at GSK, a position she has held since July 2022. As the lead for global real-world evidence and health outcomes research, her primary responsibilities involve overseeing research initiatives, developing strategic plans, and collaborating with cross-functional teams to drive business growth and improve health outcomes. Given the limited information, specific achievements and industry impact in her current role are not detailed.

Career Progression

Due to the limited information available, a detailed career progression cannot be provided. However, her current role as Director, Global RWE & Health Outcomes Research Lead (GenMed) at GSK indicates a career trajectory focused on leadership and research within the pharmaceutical industry.

Academic Background

Ines Palomares Sancho's academic background is not specified, therefore, details regarding her highest level of education, relevant specializations, and notable academic achievements cannot be provided.

Areas of Expertise

While specific areas of expertise are not detailed, her current role suggests proficiency in real-world evidence, health outcomes research, and strategic planning. Her leadership position also implies strong leadership and management capabilities.

Professional Impact

Without additional information, specific notable projects, industry contributions, or measurable achievements cannot be highlighted.

Conclusion

Ines Palomares Sancho's professional trajectory is marked by her current leadership role at GSK, focusing on global real-world evidence and health outcomes research. With her expertise and experience, she is poised to continue making significant contributions to the pharmaceutical industry. Her value proposition lies in her ability to lead research initiatives and drive strategic plans that improve health outcomes and business growth.